# Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19

> **NCT05813600** · NA · COMPLETED · sponsor: **Xiangao Jiang** · enrollment: 58 (actual)

## Conditions studied

- Omicron Variant of COVID-19

## Interventions

- **DRUG:** Nirmatrelvir/Ritonavir

## Key facts

- **NCT ID:** NCT05813600
- **Lead sponsor:** Xiangao Jiang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05813600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05813600, "Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05813600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*